Latest news with #VanHimbergen
Yahoo
4 days ago
- Business
- Yahoo
CFOs On the Move: Week ending May 30
This story was originally published on To receive daily news and insights, subscribe to our free daily newsletter. Due to family reasons, will step down as finance chief of Vertiv, a critical digital infrastructure and continuity solutions provider. A search will be launched for Fallon's successor. Fallon, who has been CFO since 2017, will retire once his successor is named and assumes the role, which is expected in the second half of the year. To help with the transition, Fallon will work as a consultant on his retirement date and through Dec. 31, 2026. Athenahealth appointed Tom Cowhey as the health IT company and electronic health record vendor's new chief financial officer, effective June 9. Cowhey was most recently the CFO of the health care company CVS Health. Before that, he was CFO at Surgery Partners, an independent operator of short-stay and ambulatory surgical facilities. He previously held several roles at Aetna, including as chief financial officer of Aetna's U.S. health plan business. Cowhey replaces John Hofmann, who stepped down late last year. The company operated with an interim finance chief while it searched for his successor. will take over as finance chief of Elanco Animal Health on July 7. VanHimbergen is currently CFO of Hillenbrand, a role he has held since March 2022. He earlier spent 15 years at Johnson Controls, where he held several financial leadership positions, including as CFO of its $9 billion automotive interiors business in China, and led the battery division in Asia. He started his career at PricewaterhouseCoopers, where he spent almost 10 years working with multinational companies. VanHimbergen succeeds Todd Young, who will stay with the company as an adviser through Aug. 31. Lyra Health, a workforce mental health benefits provider, named as CFO, effective June 16. Beaver joins the company from the medical aesthetics company Evolus, where she has been finance chief since 2022. Before that, she was senior vice president of finance at Experian. Earlier, she spent 16 years at global gaming company IGT, where she held several roles, culminating in CFO of its North America gaming and interactive business unit. was appointed finance chief of MindMed, a biopharmaceutical company that develops products to treat brain health disorders. Roberts was most recently the chief financial officer of Longboard Pharmaceuticals, where she helped lead it through its IPO and its $2.6 billion acquisition by Lundbeck in 2024. She has earlier held CFO roles at Lineage Cell Therapeutics, REVA Medical and Mast Therapeutics, and held senior finance positions at Alphatec Spine, Artes Medical, Stratagene and Pfizer. Urgently promoted to chief financial officer of the digital roadside and mobility assistance technology and services provider. Port, who was previously senior vice president of finance, will take over as CFO on June 6. Port was previously vice president of finance and controller of electric vehicle manufacturer Lordstown Motors. After that, he consulted with Nu Ride, which was Lordstown Motors' successor company created as part of its emergence from bankruptcy restructuring. He was previously the CFO of LED lighting products manufacturer Energy Focus. Port replaces Timothy Huffmyer, who is stepping down to pursue other opportunities. was promoted to finance chief of Jack in the Box. Hooper has held several positions over her almost 25-year career at the restaurant company, most recently as senior vice president and controller since December 2022. She has also been serving as its interim principal financial officer since October 2024, a role she has previously held two other times during her tenure. She started her career at KPMG, where she worked for seven years, most recently as a senior manager. Omnidian appointed as the solar power servicing company's new chief financial officer. Fein previously held CFO roles at free wireless phone service provider TextNow, continuous automation software provider Chef Software and RFID devices and software maker Impinj, where he guided its 2016 IPO. Fein is the founding chair of the Seattle Tech CFO community and global chair of the senior finance executive network The F Suite. Industrial technology manufacturing company Littelfuse hired as CFO, effective June 18. Khandelwal joins the company from global industrial company IDEX, where he was most recently the chief financial officer. He earlier held chief financial officer roles at packaging services and label solutions provider Multi-Color and global manufacturer CIRCOR International. He started his career at GE Appliances, where he held several positions over almost eight years, including as an FP&A manager and commercial finance manager. Khandelwal succeeds Meenal Sethna, who will stay with the company as a strategic adviser.
Yahoo
7 days ago
- Business
- Yahoo
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer
GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chief Financial Officer of Hillenbrand, Inc., where he contributed to the company's transformation into a pure-play industrial company. Prior to joining Hillenbrand, he spent 15 years at Johnson Controls where he led the global finance, accounting and reporting functions, was a member of the executive leadership team and was deeply involved in Johnson Controls' enterprise transformation initiative. He previously held roles within Johnson Controls, including CFO of the $9 billion automotive interiors business in Shanghai, China, and led the battery division in Asia. Prior to Johnson Controls, VanHimbergen spent nearly a decade at PricewaterhouseCoopers LLP working with large multi-national companies. "We are excited for Bob to join the Elanco Executive Committee to help guide the continuation of our increasing value creation. With seven consecutive quarters of growth and a portfolio of potential blockbusters in launch mode, Elanco is focused on accelerating growth, globalizing and maximizing existing innovation, supporting the next wave of innovation, expanding margins, and improving cash generation," said Jeff Simmons, Elanco President and CEO. "Bob's nearly three decades of experience leading finance organizations, along with his leadership style focused on value creation will be extremely beneficial to build on our current momentum as we maximize the opportunity in front of us." "I am thrilled to join Elanco at this exciting time with the company's momentum and diverse portfolio of innovation," commented VanHimbergen. "I look forward to working with the leadership team to execute on the company's strategy, accelerate growth and enhance shareholder value." Simmons continued, "On behalf of the entire Elanco organization, we are grateful for Todd's contributions as we stood up Elanco as an independent company, completed acquisitions to diversify our portfolio, increased our global scale, delivered innovation, enhanced capabilities and took important steps to pay down debt. I express my appreciation to Todd for his more than six years of leadership with the Elanco team and enhancing animal health. I greatly value everything Todd has done to put Elanco in a position of strength. This is the right time for a proactive change." "It has been my privilege to work alongside such a dedicated Elanco team to position the company for its next stage of growth," said Todd Young. "Elanco is well positioned to execute its strategy, and I look forward to supporting this transition." The company also reconfirms the second quarter and full year guidance issued on the first quarter earnings call on May 7, 2025. ABOUT ELANCOElanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at Cautionary Statement Regarding Forward-Looking StatementsThe reconfirmation of guidance contained in this press release involves forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following: operating in a highly competitive industry; the success of our research and development (R&D), regulatory approval and licensing efforts; the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein; competition from generic products that may be viewed as more cost-effective; changes in regulatory restrictions on the use of antibiotics in farm animals; an outbreak of infectious disease carried by farm animals; risks related to the evaluation of animals; consolidation of our customers and distributors; the impact of increased or decreased sales into our distribution channels resulting in fluctuations in our revenues; our dependence on the success of our top products; our ability to complete acquisitions and divestitures and to successfully integrate the businesses we acquire; our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements; manufacturing problems and capacity imbalances, including at our contract manufacturers; fluctuations in inventory levels in our distribution channels; risks related to the use of artificial intelligence in our business; our dependence on sophisticated information technology systems and infrastructure, including the use of third-party, cloud-based technologies, and the impact of outages or breaches of the information technology systems and infrastructure we rely on; the impact of weather conditions, including those related to climate change, and the availability of natural resources; demand, supply and operational challenges associated with the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern; the loss of key personnel or highly skilled employees; adverse effects of labor disputes, strikes and/or work stoppages; the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that limit our operating flexibility and changes in our credit ratings that lead to higher borrowing expenses and restrict access to credit; changes in interest rates that adversely affect our earnings and cash flows; risks related to the write-down of goodwill or identifiable intangible assets; the lack of availability or significant increases in the cost of raw materials; risks related to foreign and domestic economic, political, legal and business environments; risks related to foreign currency exchange rate fluctuations; risks related to underfunded pension plan liabilities; our current plan not to pay dividends and restrictions on our ability to pay dividends; the potential impact that actions by activist shareholders could have on the pursuit of our business strategies; risks related to tax expense or exposures; actions by regulatory bodies, including as a result of their interpretation of studies on product safety; the possible slowing or cessation of acceptance and/or adoption of our farm animal sustainability initiatives; the impact of increased regulation or decreased governmental financial support related to the raising, processing or consumption of farm animals; risks related to tariffs, trade protection measures or other modifications of foreign trade policy; the impact of litigation, regulatory investigations and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters; challenges to our intellectual property rights or our alleged violation of rights of others; misuse, off-label or counterfeiting use of our products; unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products; insufficient insurance coverage against hazards and claims; compliance with privacy laws and security of information; risks related to environmental, health and safety laws and regulations; and inability to achieve goals or meet expectations of stakeholders with respect to environmental, social and governance matters. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this press release. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this press release. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data. Investor Contact: Tiffany Kanaga (765) 740-0314 Contact: Colleen Dekker (317) 989-7011 View original content to download multimedia: SOURCE Elanco Animal Health Sign in to access your portfolio
